Related Experiment Video

Updated: Apr 20, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.8K

Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice

X Ye1, J Qi1, Y Wu1

  • 1Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, 150030 Harbin, China.

Diabetes & Metabolism
|December 3, 2014
PubMed
Abstract

Insights

PEGylated fibroblast growth factor (FGF)-21 demonstrates superior long-acting antidiabetic effects compared to insulin glargine in mice. This novel FGF-21 therapy shows significant promise for treating type 2 diabetes.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Endocrinology

Background:

  • Type 2 diabetes is a metabolic disorder characterized by hyperglycemia and insulin resistance.
  • Current treatments for type 2 diabetes often require frequent administration and can have side effects.

Purpose of the Study:

  • To evaluate the long-acting antidiabetic efficacy of PEGylated fibroblast growth factor (FGF)-21.
  • To compare PEGylated FGF-21 with insulin glargine in a mouse model of type 2 diabetes.

Main Methods:

  • PEGylated FGF-21 was synthesized by modifying human FGF-21.
  • Pharmacological efficacy was assessed in db/db mice by monitoring blood glucose, body weight, insulin, HbA1c, lipid profile, liver function, and oral glucose tolerance tests (OGTTs).

Main Results:

  • Both PEGylated FGF-21 and insulin glargine reduced plasma glucose levels.
  • PEGylated FGF-21 exhibited more significant improvements in glycemic control, lipid profile, liver function, and insulin sensitivity compared to insulin glargine.
  • PEGylated FGF-21 reduced the glucose area under the curve during OGTTs more effectively than insulin glargine.

Conclusions:

  • PEGylated FGF-21 demonstrates potent and sustained antidiabetic effects.
  • PEGylated FGF-21 is a promising therapeutic candidate for type 2 diabetes treatment.
Keywords:
DiabetesFGF-21Hypoglycaemic effectInsulin glarginePEGylation

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K
Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer16:59

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

12.2K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
3
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K